Abiraterone acetate is a medication used to treat prostate cancer. It is sold under the brand name Zytiga. More specifically it is used together with a corticosteroid for castration-resistant prostate cancer or mCRPC and metastatic high-risk metastatic castration-sensitive prostate cancer or mCSPC. It should be used in cases following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is an oral medication. Common side effects are such as tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include adrenocortical insufficiency and liver failure. Birth control is recommended in males whose partners can become pregnant. Supplied as abiraterone acetate it is converted in the body to abiraterone. Abiraterone acetate suppresses the production of androgens, specifically, it inhibits CYP17A1 and decreases the production of testosterone. Thus it prevents the effects of these hormones in prostate cancer. Abiraterone acetate was demonstrated in 1995 and gained approval for medical use in the United States and Europe in 2011. The World Health Organization listed in Essential Medicines, as the safest and most effective medicines needed in a health system. This medication is marketed widely throughout the world. Abiraterone acetate is used in combination with prednisone a corticosteroid, as a treatment for mCRPC (previously known as hormone-resistant or hormone-refractory prostate cancer). This is a kind of prostate cancer that does not respond to first-line androgen deprivation therapy or treatment with androgen receptor antagonists. Abiraterone acetate has received approval from: Food and Drug Administration (FDA) (28 April 2011), European Medicines Agency (EMA) (23 September 2011), Medicines and Healthcare products Regulatory Agency (MHRA) (5 September 2011) And Therapeutic Goods Administration (TGA) (1 March 2012) for this indication. it is covered by the Pharmaceutical Benefits Scheme In Australia, specifically when it is used to treat castration-resistant prostate cancer in combination with prednisone/prednisolone. The patient who is not currently receiving chemotherapy has been found either resistant or intolerant of docetaxel. The patient has a WHO performance status of 2. Besides his disease has not become progressive since treatment with PBS-subsidised abiraterone acetate has commenced. Contraindications include hypersensitivity to abiraterone acetate. Although documents state that it should not be taken by women. Specifically, who are pregnant or may become pregnant. There is no medical reason for any woman to take it. Pregnant women should not even touch the pills unless they are wearing gloves. Other cautions include: severe baseline hepatic impairment, mineralocorticoid excess, cardiovascular disease like heart failure and hypertension, uncorrected hypokalemia.

Abiraterone works by stopping the body’s production of a hormone called testosterone. It is usually done in a different way to other types of hormone therapy. Prostate cancer cells can't grow without testosterone, in most men. Even if they have spread to other parts of the body, they can't grow without it.

An online search for the wholesale price for sale of Abiraterone Acetate for distributors will reveal a wide range of costs. It will vary from store to store depending on your visit and the country of the wholesale market. The wholesale price of this pharmaceutical substance is around $50-65 USD per medicine. The price may vary and depends on the pharmacy you visit.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Abiraterone Acetate distributors offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and this substance Abiraterone Acetate suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Abiraterone Acetate. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Abiraterone Acetate is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical product deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers Abiraterone Acetate suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Abiraterone Acetate Manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.